Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3Phase NA 2

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Glioblastoma 7Multiple Myeloma 6Lymphoma, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Glioma 3Astrocytoma 3Sarcoma 2Melanoma 2Lymphoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metastatic Hormone-Sensitive Prostate Cancer 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 58Rituximab 54fludarabine 33fludarabine phosphate 32venetoclax 24Filgrastim 22Etoposide 18Bendamustine Hydrochloride 18Gemcitabine 17Peripheral Blood Stem Cell Transplantation 15Bortezomib 15Melphalan 14obinutuzumab 13Lenalidomide 12Dexamethasone 12Cytarabine 12Vincristine 11Vorinostat 10Tacrolimus 10Azacitidine 10pembrolizumab 9Prednisone 9Mycophenolic Acid 9Doxorubicin 9ibrutinib 8copanlisib 8Whole-Body Irradiation 8Radiotherapy 8Paclitaxel 8Interleukin-2 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Non-Hodgkin × Leukapheresis × Clear all
NCT01087294 2026-06-01

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
85 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT00968760 2023-12-19

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
34 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡